Respiratory syncytial virus RNA (RSV RNA)

Respiratory syncytial virus (RSV) RNA is the negative-sense, single-stranded genetic material of the virus, spanning approximately 15.2 kilobases and encoding 11 proteins (Collins & Karron, 2013). It serves as the essential template for both transcription into messenger RNA (mRNA) and replication into new genomic RNA via the viral RNA-dependent RNA polymerase (RdRp). In the context of disease, RSV RNA is the driver of viral proliferation, leading to severe respiratory conditions such as bronchiolitis and pneumonia, particularly in infants and the elderly (Hall et al., 2009). As a therapeutic target, RSV RNA can be directly silenced using RNA interference (RNAi) technologies, such as ALN-RSV01, which targets the nucleocapsid (N) gene mRNA to prevent protein synthesis (DeVincenzo et al., 2010). Additionally, small molecule nucleoside analogs like lumicitabine act as chain terminators that disrupt the synthesis of RSV RNA by the RdRp complex (Wang et al., 2015). Targeting the RNA directly provides a high degree of sequence specificity, potentially reducing the risk of side effects compared to systemic antivirals. However, the primary challenges in targeting RSV RNA include achieving effective drug delivery to the respiratory epithelium and the emergence of viral resistance through sequence mutations (Beigel et al., 2019). Monitoring RSV RNA levels through quantitative PCR is a standard biomarker for assessing the efficacy of these antiviral interventions in clinical trials.

Other names

RSV genomeRSV mRNARespiratory syncytial virus genomic RNARSV negative-sense single-stranded RNA

Inhibition of viral replication through RNA interference (RNAi) targeting specific viral sequences, or through the inhibition of the viral RNA-dependent RNA polymerase (RdRp) which prevents the synthesis of genomic and messenger RNA (DeVincenzo et al., 2010; Wang et al., 2015).